In an in vitro study, trastuzumab-resistant HER2-positive SKBR3 cells could form endothelial-independent tubular structures, in contrast to the parental HER2-positive SKBR3 breast cancer cells [28]. Here, ERBB2 is linked to breast carcinoma.